neokestose | 3688-75-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: neokestose
• 英文别名: β-D-fructofuranosyl-(0O!⁶-β-D-fructofuranosyl-α-D-glucopyranoside)；β-D-Fructofuranosyl-(0O!⁶-β-D-fructofuranosyl-α-D-glucopyranosid)；6G-kestotriose；(2R,3R,4S,5S,6R)-2-[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]oxane-3,4,5-triol
• CAS: 3688-75-3
• 化学式: C₁₈H₃₂O₁₆
• 分子量: 504.442
• InChiKey: HQFMTRMPFIZQJF-OESPXIITSA-N

物化性质

• 沸点：
  902.9±65.0 °C(Predicted)
• 密度：
  1.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -5.5
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  269
• 氢给体数：
  11
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  蔗糖 在 invertase-substance from sheep's rumen 作用下， 生成 neokestose
  参考文献：
  名称：

  Howard, Biochemical Journal, 1959, vol. 71, p. 675,677

  摘要：

  DOI：

文献信息

• Formation of trisaccharides (kestoses) by pyrolysis of sucrose
  作者：Merilyn Manley-Harris、Geoffrey N. Richards

  DOI：10.1016/0008-6215(91)89045-h

  日期：1991.10

  Amorphous sucrose, containing citric acid as catalyst, undergoes thermolysis at 100 degrees to yield fructofuranosyl cation and D-glucose. The cation reacts with unchanged sucrose to form all three of the known kestoses, and also their alpha-fructofuranosyl anomers. Two of the latter are resistant to invertase hydrolysis. A new fructosylglucose disaccharide is also formed.

  含有柠檬酸作为催化剂的无定形蔗糖在100度进行热解，生成果糖呋喃糖基阳离子和D-葡萄糖。阳离子与未改变的蔗糖反应形成所有三种已知的蔗糖，以及它们的α-果糖呋喃糖基异构体。后者中的两个抗转化酶水解。还形成了新的果糖基葡萄糖二糖。
• Gross et al., Journal of the Chemical Society, 1954, p. 1727,1728, 1729
  作者：Gross et al.

  DOI：——

  日期：——
• Allen; Bacon, Biochemical Journal, 1956, vol. 63, p. 200,202
  作者：Allen、Bacon

  DOI：——

  日期：——
• NMR structural study of fructans produced by Bacillus sp. 3B6, bacterium isolated in cloud water
  作者：Mária Matulová、Slavomíra Husárová、Peter Capek、Martine Sancelme、Anne-Marie Delort

  DOI：10.1016/j.carres.2010.12.012

  日期：2011.3

  Bacillus sp. 3B6, bacterium isolated from cloud water, was incubated on sucrose for exopolysaccharide production. Dialysis of the obtained mixture (MWCO 500) afforded dialyzate (DIM) and retentate (RIM). Both were separated by size exclusion chromatography. RIM afforded eight fractions: levan exopolysaccharide (EPS), fructooligosaccharides (FOSs) of levan and inulin types with different degrees of polymerization (dp 2-7) and monosaccharides fructose:glucose = 9:1. Levan was composed of two components with molecular mass similar to 3500 and similar to 100 kDa in the ratio 2.3:1. Disaccharide fraction contained difructose anhydride DFA IV. 1-Kestose, 6-kestose, and neokestose were identified as trisaccharides in the ratio 2:1:3. Fractions with dp 4-7 were mixtures of FOSs of levan (2,6-beta Fruf) and inulin (1,2-beta Fruf) type. DIM separation afforded two dominant fractions: monosaccharides with fructose: glucose ratio 1:3; disaccharide fraction contained sucrose only. DIM trisaccharide fraction contained 1-kestose, 6-kestose, and neokestose in the ratio1.5:1:2, penta and hexasaccharide fractions contained FOSs of levan type (2,6-beta Fruf) containing alpha-glucose. In the pentasaccharide fraction also the presence of a homopentasaccharide composed of 2,6-linked beta Fruf units only was identified. Nystose, inulin (1,2-beta Fruf) type, was identified as DIM tetrasaccharide. Identification of levan 2,6-beta Fruf and inulin 1,2-beta Fruf type oligosaccharides in the incubation medium suggests both levansucrase and inulosucrase enzymes activity in Bacillus sp. 3B6. (C) 2010 Elsevier Ltd. All rights reserved.
• Synergistic Anti-Diabetic Compositions
  申请人：Ozstar Therapeutics Pty Ltd

  公开号：US20140303118A1

  公开（公告）日：2014-10-09

  The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular, the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (DP) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of Type-2 Diabetes Meliitus (T2DM). Said compositions are also used for preventing the development of or ameliorating, side-effects or conditions in a subject treated with sulfonylurea and/or a sulfonamide compounds (and/or derivatives and/or metabolites thereof, or combinations thereof), said side-effects including hypoglycemia, gastrointestinal disturbances, fatigue, weight gain, and satiety.